Renalis develops digital therapeutics for treating pelvic health disorders. The company’s flagship product, CeCe, allows users to track and manage symptoms of overactive bladder disease via a mobile application.
The startup raised USD 0.8 million in a pre-seed funding round led by the Healthcare Collaboration Fund in September 2021, which was allocated toward expediting its commercialization process by enhancing its research within hospital systems such as University Hospitals, obtaining FDA approval, and hiring additional employees for the development of its digital therapeutics technology. The company also planned to launch FDA-approved digital solutions for menstrual disorders, stress incontinence, bowel dysfunction, and chronic pelvic pain.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.